Vivos Therapeutics (VVOS) News Today $2.19 -0.06 (-2.67%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$2.28 +0.10 (+4.34%) As of 04/15/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Vivos Therapeutics price target lowered to $5.50 from $6 at Alliance Global PartnersApril 2, 2025 | markets.businessinsider.comVivos Therapeutics’ Earnings Call Highlights Growth and ExpansionApril 1, 2025 | tipranks.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comVivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call TranscriptApril 1, 2025 | seekingalpha.comVivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational UpdateMarch 31, 2025 | globenewswire.com4VVOS : Earnings Outlook For Vivos TherapeuticsMarch 28, 2025 | benzinga.comVivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference CallMarch 28, 2025 | globenewswire.comVivos Therapeutics expands strategic alliance with Rebis HealthFebruary 25, 2025 | markets.businessinsider.comVivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions NationwideFebruary 24, 2025 | markets.businessinsider.comVivos Therapeutics sees strong adoption of OSA treatment, expands strategic allianceFebruary 24, 2025 | proactiveinvestors.comVivos Therapeutics Enters Market Offering Agreement with WainwrightFebruary 14, 2025 | tipranks.comVivos Therapeutics files $50M mixed securities shelfFebruary 11, 2025 | markets.businessinsider.comVivos Therapeutics files to sell 854,332 shares of common stock for holdersJanuary 22, 2025 | markets.businessinsider.comVivos to sell 709,220 shares at $4.935 in registered direct offeringDecember 23, 2024 | markets.businessinsider.comVivos Therapeutics announces funding boostDecember 23, 2024 | proactiveinvestors.comVivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesDecember 23, 2024 | globenewswire.comVivos Therapeutics price target lowered to $6 from $8.25 at Alliance Global PartnersNovember 19, 2024 | markets.businessinsider.comVivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...November 16, 2024 | finance.yahoo.comVivos Therapeutics Reports Revenue Growth and Strategic MilestonesNovember 16, 2024 | markets.businessinsider.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comVivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational UpdateNovember 15, 2024 | markets.businessinsider.comVivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | seekingalpha.comVivos Therapeutics eyes positive cash flow as it continues cost-reduction success in Q3November 14, 2024 | proactiveinvestors.comVivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference CallNovember 13, 2024 | globenewswire.comInvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces AMA Issues CPT Codes, Coverage for Vivos CARE Oral Medical DevicesOctober 9, 2024 | msn.comVivos Therapeutics wins approval for streamlined insurance reimbursement for sleep apnea treatmentOctober 8, 2024 | proactiveinvestors.comVivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical AssociationOctober 8, 2024 | globenewswire.comTinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct OfferingSeptember 20, 2024 | msn.comVivos Therapeutics Shares Drop 27% After Pricing of Common Stock OfferingSeptember 19, 2024 | marketwatch.comVivos Therapeutics Offers Of 1.363 Mln Shares At $3.15/share, Pre-Market Stock DownSeptember 19, 2024 | markets.businessinsider.comWhy Vivos Therapeutics (VVOS) Stock Is Down 25% TodaySeptember 19, 2024 | msn.comVivos Therapeutics raises $4.3 from institutional investorsSeptember 19, 2024 | proactiveinvestors.comVivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesSeptember 19, 2024 | finance.yahoo.comVivos Therapeutics, Inc: Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and SnoringSeptember 18, 2024 | finanznachrichten.deVivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea TreatmentSeptember 18, 2024 | marketwatch.comVivos Therapeutics Gets FDA 510(k) Clearance To Treat Pediatric Sleep Apnea, Snoring; Stock UpSeptember 18, 2024 | markets.businessinsider.comVivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In ChildrenSeptember 18, 2024 | finance.yahoo.comVivos Therapeutics' oral device approved by FDA for pediatric sleep apnea treatmentSeptember 18, 2024 | proactiveinvestors.comVivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and SnoringSeptember 18, 2024 | globenewswire.com3 Trending Biotech Penny StocksAugust 22, 2024 | 247wallst.comVVOS Stock Earnings: Vivos Therapeutics Beats EPS, Beats Revenue for Q2 2024August 15, 2024 | markets.businessinsider.comInvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report on Q2 2024 Financial Results, Operational UpdateAugust 15, 2024 | msn.comVivos Therapeutics boosts Q2 revenue, cuts operating losses amid new strategic partnershipsAugust 14, 2024 | proactiveinvestors.comVivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateAugust 14, 2024 | globenewswire.comVivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference CallAugust 14, 2024 | stockhouse.comInvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans Release of Q2 2024 Financial Results, Conference CallAugust 14, 2024 | msn.comVivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference CallAugust 14, 2024 | globenewswire.comVivos Therapeutics reports positive results from pilot of provider-based modelJune 27, 2024 | proactiveinvestors.comVivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution ModelJune 27, 2024 | globenewswire.comVivos Therapeutics announces strategic alliance and $7.5M investmentJune 12, 2024 | proactiveinvestors.com Remove Ads Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address VVOS Media Mentions By Week VVOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VVOS News Sentiment▼0.440.79▲Average Medical News Sentiment VVOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VVOS Articles This Week▼21▲VVOS Articles Average Week Remove Ads Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Inovio Pharmaceuticals News Today Nutriband News Today Edap Tms News Today Microbot Medical News Today Fractyl Health News Today Hyperfine News Today SurgePays News Today iCAD News Today Alpha Pro Tech News Today Titan Medical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VVOS) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VVOS Stock Free VVOS Stock Alerts